Abstract
Alzheimer’s disease (AD) has characteristic neuropathological abnormalities including regionalized neurodegeneration, neurofibrillary tangles, amyloid beta (Aβ) deposition, activation of pro-apoptotic genes, and oxidative stress. As the brain functions continue to disintegrate, there is a decline in person’s cognitive abilities, memory, mood, spontaneity, and socializing behavior. A framework that sequentially interlinks all these phenomenons under one event is lacking. Accumulating evidence has indicated the role of insulin deficiency and insulin resistance as mediators of AD neurodegeneration. Herein, we reviewed the evidence stemming from the development of diabetes agent-induced AD animal model. Striking evidence has attributed loss of insulin receptor-bearing neurons to precede or accompany initial stage of AD. This state seems to progress with AD such that, in the terminal stages, it worsens and becomes global. Oxidative stress, tau hyperphosphorylation, APP-Aβ deposition, and impaired glucose and energy metabolism have all been linked to perturbation in insulin/IGF signaling. We conclude that AD could be referred to as “type 3 diabetes”. Moreover, owing to common pathophysiology with diabetes common therapeutic regime could be effective for AD patients.
Similar content being viewed by others
References
Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 81:741–766
Ashe KH, Zahs KR (2010) Probing the biology of Alzheimer’s disease in mice. Neuron 66:631–645
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 29:353–356
Gil-Bea FJ, Solas M, Solomon A, Mugueta C, Winblad B, Kivipelto M et al (2010) Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimers disease. J Alzheimers Dis 22:405–413
Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med 23:134–147
Craft S, Cholerton B, Baker LD (2013) Insulin and Alzheimer’s disease: untangling the web. J Alzheimers Dis 33:S263–S275
Zhu X, Perry G, Smith MA (2005) Insulin signaling, diabetes mellitus and risk of Alzheimer disease. J Alzheimers Dis 7:81–84
de la Monte SM, Wands JR (2005) Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis 7:45–61
Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R et al (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease-is this type 3 diabetes? J Alzheimers Dis 7:63–80
Craft S (2012) Alzheimer disease: insulin resistance and AD—extending the translational path. Nat Rev Neurol 8:360–362
Iwangoff P, Armbruster R, Enz A, Meier-Ruge W (1980) Glycolytic enzymes from human autoptic brain cortex: normal aged and demented cases. Mech Ageing Dev 14:203–209
Schiöth HB, Craft S, Brooks SJ, Frey WH II, Benedict C (2012) Brain insulin signaling and Alzheimer’s disease: current evidence and future directions. Mol Neurobiol 46:4–10
Havel PJ (2004) Update on adipocyte hormones regulation of energy balance and carbohydrate/lipid metabolism. Diabetes 53:S143–S151
Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Porte D Jr (1992) Insulin in the brain: a hormonal regulator of energy balance. Endocr Rev 13:387–414
Havrankova J, Roth J, Brownstein M (1978) Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272:827–829
Margolis RU, Altszuler N (1967) Insulin in the cerebrospinal fluid. Nature 215:1375–1376
Boura-Halfon S, Zick Y (2009) Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab 296:E581–E591
Zhao W-Q, Alkon DL (2001) Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177:125–134
Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL (2001) Improving influence of insulin on cognitive functions in humans. Neuroendocrinology 74:270–280
Nelson TJ, Sun M-K, Hongpaisan J, Alkon DL (2008) Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair. Eur J Pharmacol 585:76–87
Benedict C, Hallschmid M, Schmitz K, Schultes B, Ratter F, Fehm HL et al (2006) Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 32:239–243
Prolla TA, Mattson MP (2001) Molecular mechanisms of brain aging and neurodegenerative disorders: lessons from dietary restriction. Trends Neurosci 24:21–31
Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D et al (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 101:3100–3105
Watson G, Craft S (2004) Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer’s disease. Eur J Pharmacol 490:97–113
Frölich L, Blum-Degen D, Bernstein H-G, Engelsberger S, Humrich J, Laufer S et al (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer’s disease. J Neural Transm 105:423–438
Suzanne M, Wands JR (2008) Alzheimer’s disease is type 3 diabetes—evidence reviewed. J Diabetes Sci Technol 2:1101–1113
Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490:115–125
Cole GM, Frautschy SA (2007) The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer’s Disease. Exp Gerontol 42:10–21
Liu X, Erikson C, Brun A (1996) Cortical synaptic changes and gliosis in normal aging, Alzheimer’s disease and frontal lobe degeneration. Dementia 7:128–134
Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong C-X (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer’s disease. Proc Natl Acad Sci USA 101:10804–10809
Watson GS, Craft S (2003) The role of insulin resistance in the pathogenesis of Alzheimer’s disease. CNS Drugs 17:27–45
Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53:474–481
Tabet N (2006) Acetylcholinesterase inhibitors for Alzheimer’s disease: anti-inflammatories in acetylcholine clothing! Age Ageing 35:336–338
Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB (2011) Diabetes mellitus and Alzheimer’s disease: shared pathology and treatment? Br J Clin Pharmacol 71:365–376
De la Monte S, Chen G, Rivera E, Wands J (2003) Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells. Cell Mol Life Sci 60:2679–2691
Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A et al (2012) Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122:1316–1338
Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM (2005) Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer’s disease: link to brain reductions in acetylcholine. J Alzheimers Dis 8:247–268
Alagiakrishnan K, Sankaralingam S, Ghosh M, Mereu L, Senior P (2013) Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer’s disease. Discov Med 16:277–286
Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA (2011) Insulin-resistant brain state: the culprit in sporadic Alzheimer’s disease? Ageing Res Rev 10:264–273
Li L, Hölscher C (2007) Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Res Rev 56:384–402
Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N (2010) Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer’s disease and diabetes mellitus. Neurobiol Dis 37:67–76
Hirosumi J, Tuncman G, Chang L, Görgün CZ, Uysal KT, Maeda K et al (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333–336
Zhao W-Q, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ et al (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22:246–260
Ma Q-L, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ et al (2009) β-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci 29:9078–9089
Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel J-C, Decker H et al (2012) An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers. J Clin Invest 122:1339–1353
Lourenco MV, Clarke JR, Frozza RL, Bomfim TR, Forny-Germano L, Batista AF et al (2013) TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer’s β-amyloid oligomers in mice and monkeys. Cell Metab 18:831–843
De Felice FG, Vieira MN, Bomfim TR, Decker H, Velasco PT, Lambert MP et al (2009) Protection of synapses against Alzheimer’s-linked toxins: insulin signaling prevents the pathogenic binding of Aβ oligomers. Proc Natl Acad Sci 106:1971–1976
Walsh DM, Selkoe DJ (2007) Aβ oligomers—a decade of discovery. J Neurochem 101:1172–1184
Negash S, Bennett DA, Wilson RS, Schneider JA, Arnold SE (2011) Cognition and neuropathology in aging: multidimensional perspectives from the Rush Religious Orders Study and Rush Memory and Aging Project. Curr Alzheimer Res 8:336
Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R et al (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–580
Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M et al (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448–6453
Bjorklund NL, Reese LC, Sadagoparamanujam V, Ghirardi V, Woltjer RL, Taglialatela G (2012) Absence of amyloid beta oligomers at the postsynapse and regulated synaptic Zn2+ in cognitively intact aged individuals with Alzheimer’s disease neuropathology. Mol Neurodegener 7:23
Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE et al (2003) Alzheimer’s disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci 100:10417–10422
Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M et al (2010) High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24:2716–2726
Ferreira ST, Vieira MN, De Felice FG (2007) Soluble protein oligomers as emerging toxins in Alzheimer’s and other amyloid diseases. IUBMB Life 59:332–345
Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat Rev Mol Cell Biol 8:101–112
Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M et al (2007) Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci 27:796–807
Jurgensen S, Antonio LL, Mussi GE, Brito-Moreira J, Bomfim TR, De Felice FG et al (2011) Activation of D1/D5 dopamine receptors protects neurons from synapse dysfunction induced by amyloid-beta oligomers. J Biol Chem 286:3270–3276
De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN et al (2008) Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Neurobiol Aging 29:1334–1347
De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST et al (2007) Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590–11601
Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer’s disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31:224–243
Klein WL, Krafft GA, Zhao W-Q (2011) Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance. Google Patents
Craft S (2006) Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 20:298–301
de la Monte SM, Longato L, Tong M, Wands JR (2009) Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs 10:1049–1060
de la Monte SM, Tong M (2009) Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer’s disease. J Alzheimers Dis 17:817–825
Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease. J Alzheimers Dis 9:13–33
Duelli R, Schröck H, Kuschinsky W, Hoyer S (1994) Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int J Dev Neurosci 12:737–743
de la Monte SM, Tong M, Lester-Coll N, Plater J, Michael Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease. J Alzheimers Dis 10:89–109
Tong M, Longato L, de la Monte SM (2010) Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration. BMC Endocr Disord 10:4
Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z et al (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J 18:902–904
Gallagher J, Minogue A, Lynch M (2012) Impaired performance of female APP/PS1 mice in the Morris water maze is coupled with increased Aβ accumulation and microglial activation. Neurodegener Dis 11:33–41
Watson G, Bernhardt T, Reger MA, Cholerton BA, Baker LD, Peskind ER et al (2006) Insulin effects on CSF norepinephrine and cognition in Alzheimer’s disease. Neurobiol Aging 27:38–41
Reger M, Watson G, Green P, Wilkinson C, Baker L, Cholerton B et al (2008) Intranasal insulin improves cognition and modulates β-amyloid in early AD. Neurology 70:440–448
Li Y, Duffy KB, Ottinger MA, Ray B, Bailey JA, Holloway HW et al (2010) GLP-1 receptor stimulation reduces amyloid-β peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer’s disease. J Alzheimers Dis 19:1205–1219
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflict of interest pertaining to this review.
Rights and permissions
About this article
Cite this article
Ahmed, S., Mahmood, Z. & Zahid, S. Linking insulin with Alzheimer’s disease: emergence as type III diabetes. Neurol Sci 36, 1763–1769 (2015). https://doi.org/10.1007/s10072-015-2352-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-015-2352-5